PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market

Executive Summary

• PharmaTher announced a strategic initiative to expand its PharmaPatch™ microneedle patch platform into select therapeutic peptides for the U.S. market.
• The company is evaluating feasibility for peptide candidates BPC‑157, GHK‑Cu, TB‑500, KPV and potential combinations, leveraging its existing ketamine and psychedelic patch experience.
• Market context highlights a rapidly growing U.S. peptide therapeutics market projected to reach ~US$160 billion by 2030, with PharmaTher positioning the patch platform as a needle‑free, at‑home delivery solution.

Key Details

• Strategic Goal: Broaden PharmaPatch™ from ketamine/psychedelics to therapeutic peptides, aiming for improved patient adherence and convenience.
• Regulatory Landscape: Monitoring U.S. policy discussions on peptide accessibility; referenced remarks by HHS Secretary Robert F. Kennedy Jr. on potential FDA actions.
• Market Opportunity: Grand View Research estimates the U.S. peptide therapeutics market was US$65.1 billion in 2024, projected to reach US$160.3 billion by 2030 (14.7% CAGR).
• Peptide Candidates Under Evaluation:
• BPC‑157
• GHK‑Cu (copper tripeptide‑1)
• TB‑500 (Thymosin Beta‑4 fragment)
• KPV (Lys‑Pro‑Val)
• Potential combinations of the above.
• Potential Advantages of Peptide Microneedle Patch: Needle‑free administration, at‑home convenience, controlled release profiles, ability to deliver combination therapies, and improved adherence versus injectable regimens.
• Previous PharmaPatch™ Achievements (Ketamine & Psychedelics):
• IND‑enabling PK/tolerability study for ketamine patch in minipigs – >40 h delivery, favorable tolerability.
• Microneedle research studies confirming feasibility for psilocybin, LSD, DMT, and MDMA patches (fabrication, ex‑vivo skin insertion, multi‑day release).
• Development Plan: Staged feasibility work leading to potential clinical evaluation, manufacturing/scale‑up assessment, and IP filings specific to peptide delivery.
• Intellectual Property Strategy: Anticipated filing of patents arising from peptide‑focused PharmaPatch™ work.
• Cautionary Note: All described products are investigational, for research use only; safety and efficacy not established; subject to FDA and other regulatory approvals.

Notable Quotes

“Building on our ketamine and psychedelics patch programs and our expansion into GLP‑1 delivery, we are now broadening PharmaPatch™ to evaluate select peptide candidates where a needle‑free, at‑home patch could improve real‑world use.” – Fabio Chianelli, Founder & CEO, PharmaTher

Materiality Assessment: Non-Material – Neutral (early‑stage R&D announcement without immediate financial impact).